Pharmaceutical companies Cipla and Roche India on Monday announced the launch of a coronavirus antibody drug cocktail to treat non-hospitalised patients who face high risks of their infections turning severe. The high-risk category includes patients above the age of 60, and those suffering from co-morbidities like diabetes and heart, liver and kidney ailments.
The drug, which has been developed by New York-based Regeneron Pharmaceuticals, will be imported in India by Roche Pharma and marketed and distributed through a strategic partnership with Cipla.The Central Drugs Standards Control Organisation had recently provided an emergency use authorisation for the antibody cocktail in India, the release mentioned. The drug has also received emergency use authorisation in the United States and several European Union countries.
Cipla Managing Director and Chief Executive Officer Umang Vohra tweeted about the development on Monday. “Hoping this antibody cocktail casirivimab and imdevimab provides the much needed relief to patients and healthcare system in India,” Vohra said.
The combination did not show promising result in earlier studies.